Marex Group’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Marex Group’s Portfolio KTTAW Stock Details KTTAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$223	Hold	25,000	–	–	﹤0.01%	1116
2026 Q1	$250	Hold	25,000	–	–	﹤0.01%	1004
2025 Q4	$345	Hold	25,000	–	–	﹤0.01%	961
2025 Q3	$423	Hold	25,000	–	–	﹤0.01%	838
2025 Q2	$388	Hold	25,000	–	–	﹤0.01%	641
2025 Q1	$460	Hold	25,000	–	–	﹤0.01%	682
2024 Q4	$925	Hold	25,000	–	–	﹤0.01%	675
2024 Q3	$873	Hold	25,000	–	–	﹤0.01%	604
2024 Q2	$275	Hold	25,000	–	–	﹤0.01%	635
2024 Q1	$308	Hold	25,000	–	–	﹤0.01%	478
2023 Q4	$450	Buy	+25,000	New	+$300	﹤0.01%	560

Other funds holding KTTAW

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Marex Group's KTTAW Position: Q2 2026 in Review

Marex Group held its Pasithea Therapeutics Warrants (KTTAW) position steady in Q2 2026 at 25,000 shares worth $223. The position accounts for ﹤0.01% of the portfolio, ranked #1116.

Marex Group first reported a position in KTTAW in Q4 2023 and has held it in 11 quarters since. The position peaked at $925 in Q4 2024. 6 funds tracked by Wall St. Rank hold KTTAW as of Q2 2026.

Marex Group held 25,000 shares of Pasithea Therapeutics Warrants worth $223 as of Q2 2026.
Marex Group left its Pasithea Therapeutics Warrants share count unchanged in Q2 2026.
Pasithea Therapeutics Warrants made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #1116 holding.
Marex Group first reported a position in Pasithea Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
Marex Group's Pasithea Therapeutics Warrants position peaked at $925 in Q4 2024.
6 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.